{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T02:42:53Z","timestamp":1761619373313},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2013,3,22]],"date-time":"2013-03-22T00:00:00Z","timestamp":1363910400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1007\/s00105-012-2467-z","type":"journal-article","created":{"date-parts":[[2013,3,20]],"date-time":"2013-03-20T14:57:13Z","timestamp":1363791433000},"page":"263-268","source":"Crossref","is-referenced-by-count":3,"title":["Isotretinoin"],"prefix":"10.1007","volume":"64","author":[{"given":"A.","family":"Thielitz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Gollnick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,3,22]]},"reference":[{"key":"2467_CR1","unstructured":"Alhusayen RO, Juurlink DN, Mamdani MM et al (2012) Isotretinoin use and the risk of inflammatory bowel disease: a population-based cohort study. J Invest Dermatol [Epub ahead of print]"},{"key":"2467_CR2","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/j.1468-3083.2010.03933.x","volume":"25","author":"Borghi","year":"2011","unstructured":"Borghi A, Mantovani L, Minghetti S et al (2011) Low-cumulative dose isotretinoin treatment in mild-to-moderate acne: efficacy in achieving stable remission. J Eur Acad Dermatol Venereol 25:1094\u20131098","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2467_CR3","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1365-2133.2010.09976.x","volume":"164","author":"Crijns","year":"2011","unstructured":"Crijns HJ, Straus SM, Gispen-de WC, de Jong-van den Berg LT (2011) Compliance with pregnancy prevention programmes of isotretinoin in Europe: a systematic review. Br J Dermatol 164:238\u2013244","journal-title":"Br J Dermatol"},{"key":"2467_CR4","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1038\/ajg.2009.334","volume":"104","author":"Crockett","year":"2009","unstructured":"Crockett SD, Gulati A, Sandler RS, Kappelman MD (2009) A causal association between isotretinoin and inflammatory bowel disease has yet to be established. Am J Gastroenterol 104:2387\u20132393","journal-title":"Am J Gastroenterol"},{"key":"2467_CR5","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000248869","volume":"175","author":"Cunliffe","year":"1987","unstructured":"Cunliffe WJ, Norris JF (1987) Isotretinoin \u2013 an explanation for its long-term benefit. Dermatologica 175(Suppl 1):133\u2013137","journal-title":"Dermatologica"},{"key":"2467_CR6","first-page":"17","volume":"5","author":"Del","year":"2012","unstructured":"Del Rosso JQ (2012) Face to face with oral isotretinoin: a closer look at the spectrum of therapeutic outcomes and why some patients need repeated courses. J Clin Aesthet Dermatol 5:17\u201324","journal-title":"J Clin Aesthet Dermatol"},{"key":"2467_CR7","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1038\/jid.2012.111","volume":"132","author":"Dispenza","year":"2012","unstructured":"Dispenza MC, Wolpert EB, Gilliland KL et al (2012) Systemic isotretinoin therapy normalizes exaggerated TLR-2-mediated innate immune responses in acne patients. J Invest Dermatol 132:2198\u20132205","journal-title":"J Invest Dermatol"},{"key":"2467_CR8","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1111\/j.1610-0387.2009.07238.x","volume":"8","author":"Ganceviciene","year":"2010","unstructured":"Ganceviciene R, Zouboulis CC (2010) Isotretinoin: state of the art treatment for acne vulgaris. J Dtsch Dermatol Ges 8(Suppl 1):S47\u2013S59","journal-title":"J Dtsch Dermatol Ges"},{"key":"2467_CR9","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1365-2133.1983.tb03973.x","volume":"108","author":"Jones","year":"1983","unstructured":"Jones DH, King K, Miller AJ, Cunliffe WJ (1983) A dose-response study of I3-cis-retinoic acid in acne vulgaris. Br J Dermatol 108:333\u2013343","journal-title":"Br J Dermatol"},{"key":"2467_CR10","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/j.1365-2133.2009.09618.x","volume":"162","author":"Karadag","year":"2010","unstructured":"Karadag AS, Ertugrul DT, Tutal E, Akin KO (2010) Short-term isotretinoin treatment decreases insulin-like growth factor-1 and insulin-like growth factor binding protein-3 levels: Does isotretinoin affect growth hormone physiology? Br J Dermatol 162:798\u2013802","journal-title":"Br J Dermatol"},{"key":"2467_CR11","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1365-2133.1993.tb11849.x","volume":"129","author":"Layton","year":"1993","unstructured":"Layton AM, Knaggs H, Taylor J, Cunliffe WJ (1993) Isotretinoin for acne vulgaris \u2013 10 years later: a safe and successful treatment. Br J Dermatol 129:292\u2013296","journal-title":"Br J Dermatol"},{"key":"2467_CR12","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/j.1468-3083.2006.01671.x","volume":"20","author":"Layton","year":"2006","unstructured":"Layton AM, Dreno B, Gollnick HP, Zouboulis CC (2006) A review of the European Directive for prescribing systemic isotretinoin for acne vulgaris. J Eur Acad Dermatol Venereol 20:773\u2013776","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2467_CR13","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1111\/j.1365-2133.2010.10152.x","volume":"164","author":"Lee","year":"2011","unstructured":"Lee JW, Yoo KH, Park KY et al (2011) Effectiveness of conventional, low-dose and intermittent oral isotretinoin in the treatment of acne: a randomized, controlled comparative study. Br J Dermatol 164:1369\u20131375","journal-title":"Br J Dermatol"},{"key":"2467_CR14","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1159\/000018130","volume":"198","author":"Lehucher-Ceyrac","year":"1999","unstructured":"Lehucher-Ceyrac D, La SP de, Chastang C, Morel P (1999) Predictive factors for failure of isotretinoin treatment in acne patients: results from a cohort of 237 patients. Dermatology 198:278\u2013283","journal-title":"Dermatology"},{"key":"2467_CR15","first-page":"387","volume":"34","author":"Meigel","year":"1983","unstructured":"Meigel W, Gollnick H, Wokalek H, Plewig G (1983) Orale Behandlung der Acne conglobata mit 13-cis-Retins\u00e4ure. Ergebnisse der deutschen Multizenterstudie nach 24 Behandlungswochen. Hautarzt 34:387\u2013397","journal-title":"Hautarzt"},{"key":"2467_CR16","doi-asserted-by":"crossref","first-page":"141","DOI":"10.4161\/derm.15331","volume":"3","author":"Melnik","year":"2011","unstructured":"Melnik BC (2011) Isotretinoin and FoxO1: a scientific hypothesis. Dermatoendocrinol 3:141\u2013165","journal-title":"Dermatoendocrinol"},{"key":"2467_CR17","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1111\/j.1610-0387.2009.07312.x","volume":"8","author":"Nast","year":"2010","unstructured":"Nast A, Bayerl C, Borelli C et al (2010) S2k-Leitlinie zur Aknetherapie. J Dtsch Dermatol Ges 8(Suppl 2):s1\u2013s59","journal-title":"J Dtsch Dermatol Ges"},{"key":"2467_CR18","doi-asserted-by":"crossref","unstructured":"Nast A, Dreno B, Bettoli V et al (2012) European evidence-based (S3) guidelines for the treatment of acne. J Eur Acad Dermatol Venereol 26(Suppl 1):1\u201329. http:\/\/www.euroderm.org\/images\/stories\/guidelines\/110913_EU_Acne_Guidelines_conglobata_acne_final.pdf","DOI":"10.1111\/j.1468-3083.2011.04374.x"},{"key":"2467_CR19","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/j.1365-2133.2011.10392.x","volume":"165","author":"Nelson","year":"2011","unstructured":"Nelson AM, Cong Z, Gilliland KL, Thiboutot DM (2011) TRAIL contributes to the apoptotic effect of 13-cis retinoic acid in human sebaceous gland cells. Br J Dermatol 165:526\u2013533","journal-title":"Br J Dermatol"},{"key":"2467_CR20","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1038\/jid.2008.338","volume":"129","author":"Nelson","year":"2009","unstructured":"Nelson AM, Zhao W, Gilliland KL et al (2009) Isotretinoin temporally regulates distinct sets of genes in patient skin. J Invest Dermatol 129:1038\u20131042","journal-title":"J Invest Dermatol"},{"key":"2467_CR21","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.0022-202X.2005.23848.x","volume":"125","author":"Papakonstantinou","year":"2005","unstructured":"Papakonstantinou E, Aletras AJ, Glass E et al (2005) Matrix metalloproteinases of epithelial origin in facial sebum of patients with acne and their regulation by isotretinoin. J Invest Dermatol 125:673\u2013684","journal-title":"J Invest Dermatol"},{"key":"2467_CR22","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1159\/000090658","volume":"212","author":"Quereux","year":"2006","unstructured":"Quereux G, Volteau C, N\u2019Guyen JM, Dreno B (2006) Prospective study of risk factors of relapse after treatment of acne with oral isotretinoin. Dermatology 212:168\u2013176","journal-title":"Dermatology"},{"key":"2467_CR23","doi-asserted-by":"crossref","unstructured":"Rademaker M (2012) Isotretinoin: dose, duration and relapse. What does 30 years of usage tell us? Australas J Dermatol [Epub ahead of print]","DOI":"10.1111\/j.1440-0960.2012.00947.x"},{"key":"2467_CR24","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/j.1365-2133.2011.10440.x","volume":"165","author":"Sardana","year":"2011","unstructured":"Sardana K, Garg VK (2011) Low-dose isotretinoin in acne vulgaris: a critical review. Br J Dermatol 165:698\u2013700","journal-title":"Br J Dermatol"},{"key":"2467_CR25","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1365-2133.1993.tb11850.x","volume":"129","author":"Stainforth","year":"1993","unstructured":"Stainforth JM, Layton AM, Taylor JP, Cunliffe WJ (1993) Isotretinoin for the treatment of acne vulgaris: which factors may predict the need for more than one course? Br J Dermatol 129:297\u2013301","journal-title":"Br J Dermatol"},{"key":"2467_CR26","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S0190-9622(84)80100-0","volume":"10","author":"Strauss","year":"1984","unstructured":"Strauss JS, Rapini RP, Shalita AR et al (1984) Isotretinoin therapy for acne: results of a multicenter dose-response study. J Am Acad Dermatol 10:490\u2013496","journal-title":"J Am Acad Dermatol"},{"key":"2467_CR27","doi-asserted-by":"crossref","first-page":"c5812","DOI":"10.1136\/bmj.c5812","volume":"341","author":"Sundstr\u00f6m","year":"2010","unstructured":"Sundstr\u00f6m A, Alfredsson L, Sjolin-Forsberg G et al (2010) Association of suicide attempts with acne and treatment with isotretinoin: retrospective Swedish cohort study. BMJ 341:c5812","journal-title":"BMJ"},{"key":"2467_CR28","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/j.1365-2133.2011.10686.x","volume":"166","author":"Thiboutot","year":"2012","unstructured":"Thiboutot D, Gollnick H, Bettoli V et al (2012) Oral isotretinoin and pregnancy prevention programmes. Br J Dermatol 166:466\u2013467","journal-title":"Br J Dermatol"},{"key":"2467_CR29","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0006-291X(03)00332-2","volume":"303","author":"Karlsson","year":"2003","unstructured":"Karlsson T, Vahlquist A, Kedishvili N, Torma H (2003) 13-cis-retinoic acid competitively inhibits 3 alpha-hydroxysteroid oxidation by retinol dehydrogenase RoDH-4: a mechanism for its anti-androgenic effects in sebaceous glands? Biochem Biophys Res Commun 303:273\u2013278","journal-title":"Biochem Biophys Res Commun"},{"key":"2467_CR30","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1001\/archderm.134.3.376","volume":"134","author":"White","year":"1998","unstructured":"White GM, Chen W, Yao J, Wolde-Tsadik G (1998) Recurrence rates after the first course of isotretinoin. Arch Dermatol 134:376\u2013378","journal-title":"Arch Dermatol"},{"key":"2467_CR31","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/BF00414230","volume":"276","author":"Hennes","year":"1984","unstructured":"Hennes R, Mack A, Schell H, Vogt HJ (1984) 13-cis-retinoic acid in conglobata acne. A follow-up study of 14 trial centers. Arch Dermatol Res 276:209\u2013215","journal-title":"Arch Dermatol Res"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-012-2467-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00105-012-2467-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-012-2467-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T03:37:59Z","timestamp":1558582679000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00105-012-2467-z"}},"subtitle":["Wie behandelt man richtig?"],"short-title":[],"issued":{"date-parts":[[2013,3,22]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["2467"],"URL":"https:\/\/doi.org\/10.1007\/s00105-012-2467-z","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,22]]}}}